Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives

Table 1

Step of biosynthetic pathway, site of action, and blocking agents.

Step of biosynthetic pathway	Site of action	Blocking agent
Flap (five-lipoxygenase activating protein)	Cell membrane	Not developed commercially
5-LO (5-lipoxygenase)	Citosol	Zileuton
	Citosol	Via-2291
Translocation of 5-lipoxygenase	Binding sites	DG-031 (BAY × 1005)
	Cell membrane
CysLT1 receptor	Target cells	Montelukast
		Zafirlukast
		Pranlukast